11-35287236-C-T
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_004171.4(SLC1A2):c.1092-285G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.599 in 151,142 control chromosomes in the GnomAD database, including 27,737 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.60 ( 27737 hom., cov: 28)
Consequence
SLC1A2
NM_004171.4 intron
NM_004171.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.0320
Publications
10 publications found
Genes affected
SLC1A2 (HGNC:10940): (solute carrier family 1 member 2) This gene encodes a member of a family of solute transporter proteins. The membrane-bound protein is the principal transporter that clears the excitatory neurotransmitter glutamate from the extracellular space at synapses in the central nervous system. Glutamate clearance is necessary for proper synaptic activation and to prevent neuronal damage from excessive activation of glutamate receptors. Improper regulation of this gene is thought to be associated with several neurological disorders. Alternatively spliced transcript variants of this gene have been identified. [provided by RefSeq, Jun 2017]
SLC1A2 Gene-Disease associations (from GenCC):
- developmental and epileptic encephalopathy, 41Inheritance: AD, AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- undetermined early-onset epileptic encephalopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.59).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.713 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.599 AC: 90405AN: 151022Hom.: 27712 Cov.: 28 show subpopulations
GnomAD3 genomes
AF:
AC:
90405
AN:
151022
Hom.:
Cov.:
28
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.599 AC: 90479AN: 151142Hom.: 27737 Cov.: 28 AF XY: 0.606 AC XY: 44682AN XY: 73780 show subpopulations
GnomAD4 genome
AF:
AC:
90479
AN:
151142
Hom.:
Cov.:
28
AF XY:
AC XY:
44682
AN XY:
73780
show subpopulations
African (AFR)
AF:
AC:
18407
AN:
41148
American (AMR)
AF:
AC:
9899
AN:
15188
Ashkenazi Jewish (ASJ)
AF:
AC:
2337
AN:
3470
East Asian (EAS)
AF:
AC:
3761
AN:
5132
South Asian (SAS)
AF:
AC:
3099
AN:
4792
European-Finnish (FIN)
AF:
AC:
6852
AN:
10278
Middle Eastern (MID)
AF:
AC:
197
AN:
294
European-Non Finnish (NFE)
AF:
AC:
43975
AN:
67826
Other (OTH)
AF:
AC:
1300
AN:
2104
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
1748
3496
5243
6991
8739
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
752
1504
2256
3008
3760
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2364
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.